Compugen Updated Trial Data Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Milestone rich 2021 to include data readouts from ongoing COM701 triple combination study and COM902 monotherapy study in Q4 2021 Initiation of Phase 1b cohort expansion study of COM701 with Opdivo® in Q2 2021 and Phase 1 …
Editas Medicine Reporting Editas Medicine (EDIT) reported business highlights and financial results for the first quarter of 2021. The reporting started with James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine stating that Editas’ team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for the firm’s two . . . This content …
Gilead Sciences and Eisai Pharmaceutical Co Submitted an Application to Japan's PMDA for Filgotinib Galapagos NV (GLPG) announced that Gilead Sciences (
European Authorities Recommended Additional Approval of Bristol-Myers Squibb Product Onureg® for AML Bristol-Myers Squibb (BMY): The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Onureg® (azacitidine tablets; CC-486) as maintenance therapy in adult patients with acute myeloid leukemia (AML). The approval is for the AML . . . This content is for paid subscribers. Please click here …
Cassava Sciences Guidance and Financial Results Cassava Sciences (SAVA) announced financial results for the first quarter ended March 31, 2021 as well as its guidance regarding the release of new clinical data with simufilam, the Company’s lead drug candidate to treat Alzheimer’s disease. Investors and shareholders of this firm are impatiently waiting for more news about the firm’s . . . This content is for …
Inovio Pharmaceuticals Promising Results for INO-4800 for COVID-19 Inovio Pharmaceuticals (INO) announces promising results of a study focusing on the human immune responses induced by Inovio DNA vaccine candidate, INO-4800, against COVID-19, and variants of concern. The results demonstrated that INO-4800 induced a robust T . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
vTv Therapeutics Receives Breakthrough Therapy Designation for TTP399 vTv Therapeutics (VTVT) - a clinical-stage biopharmaceutical company focused on the development of oral treatments for type 1 diabetes, psoriasis, and other diseases, announced that the U.S. FDA has granted Breakthrough Therapy designation for TTP399 as adjunctive therapy to insulin for the treatment of type 1 diabetes. About vTv Therapeutics Product TTp399 . . . This content …
Gilead Sciences is Granted FDA Approval for Trodelvy® Gilead Sciences (GILD), a company that has been granted more approvals than many are aware of except for the short analysts and their followers, today announced that the U.S. FDA has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or . . . This content is for paid subscribers. Please click here …
Illumina Acquisition of GRAIL On September 21, 2020, Illumina and GRAIL Inc. announced that they entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion, upon closing of the transaction. On March 31, 2021, Illumina announced that it disagrees with, and will oppose, the U.S. Federal Trade Commission's (FTC) challenge to its previously announced acquisition of GRAIL. Illumina …
CureVac CureVac B.V. (CVAC) is a global biopharmaceutical company specializing in messenger RNA (mRNA) technology. The firm has more than 20 years of expertise in developing and optimizing versatile biological molecules for prevention and treatment purposes. CureVac’s proprietary technology principle is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce . . . This content is for …
AstraZeneca to Supply Additional Doses of AZD7442 to the U.S. for COVID-19 AstraZeneca (AZN) has modified an existing agreement with the U.S. Government to supply up to 500,000 additional doses of AZD7442 - a long-acting antibody (LAAB) combination in late-stage development, for the prevention and treatment of COVID-19. We stress . . . This content is for paid subscribers. Please click here to subscribe or here to …
Gilead Sciences and Merck Announced Agreement for Long-Term HIV Combination Treatment Gilead Sciences (GILD) and Merck (MRK . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Anixa Biosciences Outperformance Anixa Biosciences Inc (ANIX) is the worldwide licensee of a patent technology titled "Ovarian Cancer Vaccine" which was created at Cleveland Clinic. Anixa Therapeutics specializes in the treatment and prevention of cancer and infectious diseases. The firm made the announcement about the European Patent Office’s issuance and publication . . . This content is for paid subscribers. Please click here to subscribe or …
Updated Findings from bluebird bio bluebird bio analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in a clinical study of LentiGlobin for SCD bluebird bio initiated a process with regulators to resume clinical studies bluebird bio (BLUE)
Ovid Therapeutics & Takeda Announce Agreement for Soticlestat Ovid Pharmaceuticals is eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales Potential first-in-class therapy reduced seizure frequency in children with Dravet syndrome and Lennox-Gastaut syndrome in Phase 2 ELEKTRA study Original 2017 collaboration between Ovid and Takeda to conclude; Ovid …
Aslan Pharmaceuticals Aslan Pharmaceuticals (ASLN) is a clinical-stage immunology company announced positive interim unblinded data from three dose cohorts of its ongoing randomized, double-blind placebo-controlled multiple ascending dose study of ASLAN-004 for moderate to severe atopic dermatitis. ASLAN004 was well tolerated across all doses. It demonstrated improvements compared . . . This content is for paid subscribers. Please click here to subscribe or here to log …
bluebird bio Suspends LentiGlobin Studies bluebird bio (BLUE) placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD), bb1111, on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
